Arnesen, Harald

Berge, Trygve

Kalstad, Are A.

Laake, Kristian

Myhre, Peder L.

Schmidt, Erik B.

Seljeflot, Ingebjørg

Solheim, Svein

Tveit, Arnljot

Tveit, Sjur H.

English

Peder L. Myhre

Trygve Berge

Are A. Kalstad

Sjur H. Tveit

Kristian Laake

Erik B. Schmidt

Svein Solheim

Harald Arnesen

Ingebjørg Seljeflot

Arnljot Tveit

Crossref

Omega-3 fatty acid supplements and risk of atrial fibrillation and ‘micro-atrial fibrillation’: A secondary analysis from the OMEMI trial

BACKGROUND &amp; AIMS: Recent randomized clinical trials have raised concerns regarding potential off target adverse effects from supplementation of n-3 polyunsaturated fatty acids (PUFA) on atrial fibrillation (AF) risk. We aimed to assess risk and potential mediators of AF and 'micro-AF' from n-3 PUFA in post-myocardial infarction (MI) patients.METHODS: In the OMEMI trial, 70-82 y. o. patients with a recent MI were randomized to 1.8 g/day of eicosapentaenoic-/docosahexaenoic acid (EPA/DHA) or placebo (corn oil) for two years. New-onset AF and 'micro-AF' was recorded by clinical detection and by screening with Zenicor thumb-ECG (adjudicated by blinded investigators). Serum EPA and DHA were measured at baseline and study end.RESULTS: At baseline, 759 of 1014 (75%) patients had no AF history. These patients were aged 75 ± 4 years and 71% were male. During follow-up, 43 patients developed new-onset AF (39 clinically-detected and 4 by thumb-ECG screening). In addition, 27 patients had episodes of micro-AF, yielding a total of 70 patients with new-onset AF or 'micro-AF'. In the n-3 PUFA group 46 (11.9%) had AF/'micro-AF' (28 AF, 18 'micro-AF') and in the placebo group 24 (6.5%) had AF/micro-AF (15 AF, 9 micro-AF); HR 1.90 (95%CI 1.16-3.11), P = 0.011. Changes in serum EPA (but not DHA) mediated the effect from n-3 PUFA on AF risk, explaining 65% of the association.CONCLUSION: Supplementation of n-3 PUFA post MI increases the risk of 'micro-AF' and AF, and increases in EPA seems to be an important mediator of the treatment effect from n-3 PUFA on the risk of AF.STUDY REGISTRATION: OMEMI Study; ClinicalTrails.gov identifier: NCT0184194.</p

VBN (Videnbasen)  Aalborg Universitets forskningsportal

Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': A secondary analysis from the OMEMI trial

https://vbn.aau.dk/files/545625665/Myhre_et_al._2023_._mega-3_fatty_acid_supplements_and_risk_of_atrial_fibrillation_and_micro-atrial_fibrillation_-_A_secondary_analysis_from_the_OMEMI_trial.pdf

Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation':A secondary analysis from the OMEMI trial

Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation':A secondary analysis from the OMEMI trial

Abstract

Similar works

Full text

Available Versions

Crossref

VBN (Videnbasen) Aalborg Universitets forskningsportal